FORMULATION, TECHNOLOGY AND BIOLOGICAL EVALUATION OF A BIPHASIC GEL FOR WOUND HEALING

Abstract

Disruption of the integrity of human skin, leading to wounds, poses a significant threat to the human body. Wound healing is crucial for achieving both functional and cosmetic outcomes. The healing process largely depends on various internal and external factors, including the form of medication used. Currently, biphasic gel (bigels) are considered promising drug formulations due to their ability to penetrate the skin effectively. Therefore, they are often used for both local and transdermal drug delivery. Based on conducted biopharmaceutical studies, the formulation for a wound-healing biphasic gel has been determined, consisting of the following components: silver sulfadiazine - 1.0%; isopropyl miristate - 7.0%; cedar oil – 17.0%; camphor - 1.0%; eucalyptus essential oil - 0.5%; soy lecithin - 1.5%; polysorbate 80 - 5.0%; methylcellulose - 2.5%; beta-cyclodextrin - 1.0%; lidocaine hydrochloride - 1.0%; Centella asiatica extract - 1.0%; aloe vera extract - 0.75%; aminocaproic acid - 1.5%; polyethylene glycol 400 - 8.0%; propylene glycol - 9.0%; sodium benzoate - 0.25%; distilled water - 42.0%. In this gel, the ratio of organogel to hydrogel is 25:75.

The technology for preparing the biphasic gel for wound healing has been developed, and a technological scheme has been proposed. This biphasic gel demonstrates a wide spectrum of significant antibacterial activity. Furthermore, the quality indicators of the proposed biphasic wound-healing gel meet the general requirements for gels.